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Introduction 1
Atrial fibrillation (AF) is a known risk factor for thromboembolic events, especially stroke and 2 transient ischemic attack (TIA) 1 . Indeed, recent data suggest that eliminating the arrhythmia may 3 achieve superior results, compared to simple rate control, in terms of survival 2 , stroke incidence 3 4 and decline in cognitive functions 4 . However, when rhythm control strategy is not indicated or fails, 5 oral anticoagulation (OAC), both with vitamin K antagonists (VKA) or novel direct oral 6 anticoalants (DOAC), is , the only treatment to prevent thromboembolic events. For these reasons 7 on a daily basis, physicians are required to perform an accurate assessment of the risk-benefit ratio 8
for VKAs or each different DOACs 5 in patients with AF, balancing the implicit bleeding risk. 9
Several clinical scores, such as the CHA 2 DS 2 -VASc score, have been proposed and more less 10 reliably identify patients potentially benefiting from OAC 6 , considering clinical variables that most 11 strongly predict not only strokes/TIAs but also AF recurrences following transcatheter ablation 7 and 12 electrical or pharmacological cardioversions 8 . Even if usually reliable, CHA 2 DS 2 -VASc score still 13 remains inadequate in several clinical circumstances, particularly in patients at low/intermediate 14 risk (i.e., CHA 2 DS 2 -VASc 1), for whom net clinical benefit of VKAs and even of DOACs is 15 seriously counterbalanced by the bleeding risk 9, 10, 11, 12 . Trying to overcome this gap in evidence and 16
recommendations, a number of alternative parameters have been investigated, evaluating their value 17 to guide clinical decision-making. Special focus, in fact, has been directed towards the left atrium 18 (LA) and left atrial appendage (LAA), as they harbour the vast majority of thrombi forming during 19 nonvalvular AF 13, 14 . 20
Aim of the present article is to methodologically review these alternative parameters and their 21 application to nonvalvular AF, discussing if and which may aid the physician in everyday activity. 
Spontaneous echocontrast and thrombi
1 Any discussion concerning LA and LAA and the risk of thromboembolic events in patients with AF 2 has to deal first with the two strongest predictors of cardioembolic stroke, the presence of thrombi 3 or spontaneous echo-contrast (SEC) in the LA or LAA 15 . The relationship between these findings 4 and the risk of subsequent cardioembolic stroke is known since the dawning of echocardiography. 5
Presence of thrombi represents the ultimate stage before the clinical event, even if their presence 6 doesn't necessarily end in peripheral embolization 16, 17 21 , to 8% in the study by Kleemann and colleagues (nonvalvular AF, CHADS 2 score 19 0-1). 20
Despite their strong and consistent ability to predict stroke and other cardioembolic events, these 21 parameters, however, present, at least, two main limitations: first, they represent an advanced grade 22 of prothrombotic state, the last step before a clinical event, so that they're rarely useful for patients 23 with recent onset of AF or at low/intermediate clinical risk in whom a decision on OAC prescription has to be made; second, these alterations are recorded by trans-esophageal 1 echocardiography (TEE) and only rarely by trans-thoracic echocardiography (TTE). 2
For these reasons, other parameters have been assessed, often referring to thrombi or SEC as 3 surrogate study end-points. During AF, LA enlargement is a common finding, as it comes both as a cause and as a consequence 8 of the arrhythmia 26,27 . Since echocardiography became available, a correlation between LA 9 dimensions as measured by antero-posterior (AP) diameter and thromboembolic risk was seeked, 10 resulting in contradictory data 28, 29, 30, 31 . In 1995, data from a prospective cohort of 1,371 men and 11 1,728 women (of whom approximately 1.8% with AF) included in the Framingham study reported a 12 significant association between LA AP diameter as measured by M-mode echocardiography and the 13 risk of stroke and death. The relative risk of stroke was 2.4 per 10 mm increment in men (95% CI, 14
1.6 to 3.7) and 1.4 in women (95% CI, 0.9 to 2.1), and, when controlling for prevalent and interim 15 AF, it remained significant, even if with a weaker association (2.0 for men, 1.2 for women) 32 . More 16 recently a study on 500 consecutive patients, admitted to hospital for stroke or TIA (15.6% with 17 AF), confirmed LA AP diameter as an independent predictor for SEC/thrombi 33 and LA AP 18 diameter, evaluated by multi-detector computed tomography (CT) in 67 patients admitted to 19 hospital for stroke was found to be significantly increased as compared to AF controls without 20 stroke 34 . On the other side, a meta-analysis performed on individual data from 1,066 patients 21 enrolled in three large clinical trials from late 80s -early 90s 35,36,37 showed that LA AP diameter 22 did not predict stroke neither at univariate analysis nor when adjusted for clinical predictors 38 . 23
Similar results arose from a prospective study assessing the prognostic implications of SEC 15 and 24 by a post-hoc analysis 39 of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial 40 , a study in which 4,060 patients with recurrent AFwere randomised to rhythm 1 control strategy vs. rate control strategy. 2
Given these data inconsistencies it becomes evident that other LA parameters need to be assessed in 3 relationship to thromboembolic events. LA area related, in AF patients, to TEE high-risk features 4 for thromboembolic events 41 and, when integrated with LV dysfunction, evidently enhanced the 5 performance of CHADS 2 and CHA 2 DS 2 -VASc clinical scores to recognize patients at high 6 thromboembolic risk 42 . However, also for LA area data are contradictory, as, for example, in the 7 1994 study by Fatkin and colleagues, no significant relationship arose between LA area and SEC or 8 LA thrombi 18 . 9
LA volume assessed by transthoracic echocardiography has been more widely tested, and, 10 especially when indexed for body surfaced (left atrial volume index, LAVI), it showed more 11 consistent interaction with clinical events. LA volume, both total and indexed for body surface, 12 significantly related to LAA thrombi at TEE examination 41,43,44 . In two distinct studies from 13 populations based in Olmsted County, increased LAVI (≥ 32 ml/mq) related to cardiovascular 14 adverse events: in the first report, enrolling 1,160 elderly patients (75.5 years) in sinus rhythm (SR), 15 the predictive value of LAVI was validated in a multivariate model 45 , while in the second study, 16 which involved 46 young adults (< 60 years) with lone AF followed for a median of 27 years, the 17 association was confirmed only in a univariate setting, due to the low number of index events 46 . 18
Although suggestive LA enlargement is strictly dependent on its underlying cause. Indeed, Ayirala 19 and colleagues reported that the predictive value of LAVI for LAA thrombi at TEE was stronger 20 when LA enlargement was associated with a reduction in LVEF 47 , while, in an Olmsted County-21 based cohort of 2,042 patients with more than 45 years (3% with a history of AF), Pritchett et al. 22 found that the relationship between LAVI and mortality did not persist when controlling for 23 diastolic dysfunction 48 , a possible predictor per se of embolic events in AF 49 . Despite the aforementioned data, however, to date, no conclusive evidence supports the use of LA enlargement 1 markers to predict embolic events in AF. 2
Eventually, progresses in magnetic resonance imaging (MRI), particularly with the development of 3 late-gadolinium enhancement (LGE) imaging, have been employed to assess structural changes of 4 atrial myocardium. Particularly, a dedicated protocol, first developed by a research group based in 5
Salt Lake City, allowed to semi-quantify LA fibrosis and to classify it in four classes based on its 6 extension (Utah classes I-IV) 50 . LA LGE extent assessed by this method related to AF recurrence 7 after ablation 51 and, more interestingly, to the presence of thrombi detected by TEE 52 and with a 8 medical history of previous stroke 53 (figure 1). Despite its brilliant promises, this technique has 9 embraced to date little diffusion, probably due to the high costs of MRI and the absence of 10 prospective validation 54 . This type of analysis is moreover penalised by the development of 11 different algorithms in different centres, a substantial limit to the standardisation of the results. For 12 this reason, a public challenge was launched trying to determine the better performing algorithm 13 and, even if no definite results were reached, this attempt may be a foundation stone in the diffusion 14 and widespread adoption of this evaluation 55 . 15 inconclusive. A paucity of data has been published and, since LAA measurements are far less 19 standardized than LA, generalizations of results and comparisons are indeed challenging. 20
Usually, LAA abnormalities are related to LA alterations 56, 57, 58 , even if some peculiar traits can be 21 found, making a dedicated analysis of LAA worth a chance. Indeed, LAA enlargement doesn't 22 always coincide with increased LA size (and viceversa) 59 , and, at least in patients in SR, LAA peak 23 flow velocity doesn't relate to any echocardiographic parameter connected with LA except than A' 1 measured at tissue-Doppler imaging (TDI) 60 . 2
Pollick and colleagues reported that a bigger maximal LAA (LAA max ) area (and not LA AP 3 diameter) as measured by TEE related to the presence of thrombi and/or SEC in 19 non-4 anticoagulated patients with valvular and nonvalvular AF 59 , and, while another study confirmed this 5 finding 61 , other laboratories failed to consistently relate LAA area to an increased risk of stroke 62 or 6 thromboembolic events 63, 64 . 7 LAA size analysis by CT or MRI also generally did not provide strong evidences in favour of a role 8 of LAA volume. Two studies reported a direct correlation between increased LAA volumes and 9 previous stroke, even after controlling for possible confounding factors, with an ideal cut-off for 10 significant risk increase at 34 ml 3 65 , but the majority of experiences did not confirm this 11 relationship 66,67,68,69 . 12
More recently, LAA morphology, by CT or MRI, has been proposed to be described in four 13 different morphologies (Cactus, Chicken Wing, Windsock and Cauliflower) based on the 14 characteristics of the main and secondary lobes 70 . By this categorization LAA morphology related 15 to thromboembolic events: it was first demonstrated that, in patients undergoing AF transcatheter 16 ablation, Chicken Wing, the most frequent LAA morphology, independently related to the absence 17 of previous stroke/TIA 69 , and that the prevalence of silent cerebral ischemic lesions increased with 18 growing complexity of LAA morphology, from Cactus, the more simple, through Chicken Wing, 19
Windsock and Cauliflower, the more complex 71 (figure 2) . Once again, further studies brought 20 controversial results: two experiences, indeed, confirmed the existence of a relationship between 21
LAA morphology and cerebrovascular events, even if with some slight differences (Kimura and 22
colleagues identified Cauliflower as the high-risk morphology 72 while other studies failed to report any correlation between LAA morphology and previous stroke 74 and incident stroke or TIA after AF ablation 67 . Concerning LAA morphology the main limitations 1 seems to relate to the reproducibility of the classification by CT or MRI 74 . More interestingly, 2 however, a recent study by Petersen and colleagues, assessed LAA morphology by three-3 dimensional (3D) TEE, which resulted non-inferior to CT and MRI [data in press], and found a 4 correlation, corroborated by multivariate linear regression analysis, between non-Chicken Wing 5
LAA morphologies and reduced LAA flow velocities 75 . These latter studies are particularly 6 promising, as validation of LAA morphology description by echocardiographic techniques may 7 enhance the routine clinical implementation of this analysis, helping to refine thromboembolic risk 8 stratification. longitudinal strain, as assessed by speckle tracking, was able to predict development of adverse 19 events including, among others, AF, stroke or TIA and cardiovascular death in 312 patients in SR 78 . 20
More in details, within AF patients, CHADS 2 and CHA 2 DS 2 -VASc scores significantly related to 21 an increased LAVI and a reduced LA emptying fraction (LAEF) in a sub-analysis of the ENGAGE 22 AF-TIMI 48 study. LAVI and LAEF also inversely related to each other, even if only LAVI was 23 confirmed as an independent predictor after adjusting for confounding factors 79 . An association 24 between LA function and CHADS 2 and CHA 2 DS 2 -VASc scores was also confirmed when LAEF was assessed by 3D echocardiography 80 . 1
In addition, since its introduction and widespread diffusion, strain analysis by speckle tracking has 2 been increasingly applied also in this field, reporting very promising results. Even if a prospective 3
validation has yet to been provided, a reduced global longitudinal strain proved to relate to the 4 extent of fibrosis at MRI 81 and not only to an increased CHADS 2 or CHA 2 DS 2 -VASc score 80,82,83 , 5 but to an improved CHADS 2 and CHA 2 DS 2 -VAScscores ability to identify patients with recent 6 acute embolic events and to predict mortality at follow up 83, 84 . Interestingly, peak negative and 7 positive atrial strain were able to discriminate patients with previous stroke or TIA in an AF-cohort 8 with low intermediate CHADS 2 score (≤ 1, of whom 30% with CHA 2 DS 2 -VASc≤ 1) 85 . 9
10
Left atrial appendage 11
LAA function has been thoroughly investigated since a correlation between reduced LAA peak 12 flow velocities (LAAv) and increased thromboembolic risk was demonstrated. LAAv tend to reduce 13 during the course of AF and more decreased values strongly related to the presence of SEC 18 , and 14 of LAA thrombi 33 and predicted cardioembolic events in a sub-analysis of the SPAF-III study 86 . 15 Despite overall consistent results, this parameter has embraced a very limited clinical 16 implementation, partly due to the variable and widely ranging cut-offs reported (in the 3 17 aforementioned studies, LAAv relating to adverse events were < 35 cm/s, < 55 cm/s and < 20 cm/s, 18 respectively 18,33,86 ), and, partly, because LAAv measurement require TEE. 19
To overcome this latter limitation, surrogate markers of reduced LAAv have been investigated. As 20 TEE studies reported a correlation between reduced LAA wall acceleration as measured by TDI and 21 increased thromboembolic risk 87, 88 , an evaluation of those TDI parameters by TTE has been 22 attempted, with garbed success. With a good feasibility (> 90%), LAA wall velocity, evaluated 23 mainly by LAA tip acceleration on a short-axis view, significantly related to reduced LAAv, 24 presence of SEC or thrombi and previous stroke 89, 90, 91 (figure 3) . Moreover, these results were 25 prospectively validate in a cohort of 179 patients with previous thromboembolic stroke related to AF, in whom an LAA wall velocity < 8.7 cm/s independently predicted recurrent stroke or 1 cerebrovascular death 92 . TDI was also used to assess septal and lateral mitral annular a' wave 2 velocities, which strongly related to reduced LAAv and SEC 60, 93 . 3
Eventually a similar proceeding than with TDI was attempted with LAA strain, even if data are, to 4 date, scarce. In fact, LAA strain predicted the presence of LAA thrombi 25 , and feasibility of the 5 evaluation by TTE was confirmed in a series of 82 patients, in whom negative peak strain rate and 6 time-to-peak positive strain independently related to the presence of LAA thrombi or sludge with an 7 AUC of 0.89 94 
Conclusion

15
LAVI and functional parameters of both LA and LAA consistently predicted stroke in patients with 16 AF, while promising results came from the application of more recent techniques such as strain and 17
LAA morphology assessment. 18
Clinical application of these parameters, however, is to date limited, mostly due to lack of large-19 scale prospective validation and consequent inability to suggest significant cut-offs. 20
In our opinion, to date, parameters, such as severely reduced LAAv or markedly enlarged LA, may 21 aid, in a case-by-case approach, as complementary tools to guide OAC prescription in controversial 22 and ambiguous cases. In addition, LAA and LA imaging, particularly with the development of 23 technologies such as TDI or speckle tracking, bears a promising potential. 
